BD to Announce Financial Results for its Second Quarter of Fiscal 2023

Rhea-AI Summary

BD (NYSE: BDX) announced that it will report its financial results for the second quarter of fiscal year 2023 on May 4, 2023. The results will be available at approximately 6:30 a.m. ET and will include summary financial information for the quarter ending March 31, 2023. An audio webcast hosted by management will follow at 8 a.m. ET on the same day, discussing financial results, operations, and strategic updates. For access, visit BD's investor relations website. BD is recognized as a global leader in medical technology, committed to enhancing healthcare delivery.

Positive

• Scheduled announcement of second-quarter financial results, providing potential insights for investors.
• Webcast allows investors direct access to management's insights on operations and strategy.

Negative

• None.

FRANKLIN LAKES, N.J., April 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its second quarter of fiscal year 2023 on Thursday, May 4, 2023. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news release and presentation materials will include summary financial information for the company's second quarter of fiscal year 2023, which ended on Friday, March 31, 2023.

BD management will host an audio webcast at 8 a.m. ET on May 4, 2023 to discuss its financial results and provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors and a replay will be available shortly after the call at the same website.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:
Media:	Investors:
Troy Kirkpatrick	Francesca DeMartino
VP, Public Relations	SVP, Head of Investor Relations
858.617.2361	201.847.5743
troy.kirkpatrick@bd.com	francesca.demartino@bd.com

   

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-to-announce-financial-results-for-its-second-quarter-of-fiscal-2023-301792057.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

When will BD report its second quarter financial results for 2023?

BD will report its second quarter financial results on May 4, 2023.

What time will the financial results be announced?

The results will be announced at approximately 6:30 a.m. ET.

How can I access the audio webcast for BD's financial results?

You can access the audio webcast on BD's investor relations website at www.bd.com/investors.

What is the financial quarter ending date for BD's upcoming report?

The financial quarter ends on March 31, 2023.

What is the significance of BD's financial results announcement?

The announcement provides insights into BD's financial health and strategic direction, impacting investor decisions.